Bleeding in Patients Undergoing CABG (Coronary Artery Bypass Graft) During Dual Antiplatelet Therapy

Acute Coronary Syndrome Clinical Trial

Official title:

Bleeding in Patients Undergoing Urgent CABG During Dual Antiplatelet Therapy Including the New P2Y12 Receptor Inhibitors Prasugrel and Ticagrelor

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02030548
• Other study ID #: NIS003684
• Status: Terminated
• Start date: November 2013
• Est. completion date: November 2016

Study information

• Verified date: June 2019
• Source: Medical University of Graz
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The aim of the study is to evaluate surgery-related bleeding and mortality in patients needing acute coronary artery bypass grafting with or without valve replacement during dual antiplatelet therapy with aspirin and a P2Y12 receptor blocker (Clopidogrel, Prasugrel, Ticagrelor)

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 144
• Est. completion date: November 2016
• Est. primary completion date: November 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

consecutive patients undergoing acute CABG with or without valve replacement within 7 days after last intake of dual antiplatelet therapy

Exclusion Criteria:

concomitant oral anticoagulants dialysis surgery employing hypothermic cardiac arrest

Related Conditions & MeSH terms

• Acute Coronary Syndrome

Locations

Country	Name	City	State
Austria	Dept. of Anesthesiology and Intensive Care Medicine	Graz	Styria

Sponsors (1)

Lead Sponsor	Collaborator
Medical University of Graz

Country where clinical trial is conducted

Austria, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	calculated blood loss		until postoperative day 5
Secondary	mortality		from index surgery until one year after index surgery